Actively Recruiting
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Led by PhotonPharma, Inc. · Updated on 2026-03-27
8
Participants Needed
1
Research Sites
41 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
CONDITIONS
Official Title
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female and age 18 years or older
- Histologically or cytologically confirmed advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Received at least one line of platinum-based systemic therapy
- Suitable for single-agent therapy as next treatment
- Received standard-of-care therapies likely to provide benefit (e.g., PARP inhibitors for BRCA mutation, bevacizumab)
- Documented relapse or progression after most recent therapy
- At least two measurable or detectable disease sites
- Able to provide at least 1.0 gram of tumor tissue for vaccine manufacturing
- Eastern Collaborative Oncology Group (ECOG) performance status 0-2
- Recovered from toxicities to Grade 2 or less (except alopecia, peripheral neuropathy, ototoxicity)
- Adequate blood, liver, and kidney function within 28 days before vaccine start
- Negative pregnancy test if of childbearing potential and agree to use contraception
- Provided written informed consent
You will not qualify if you...
- Positive history of HIV, HCV, HBV, or HTLV-1/2 infections
- Diagnosed immunodeficiency, primary or acquired
- Active or previous autoimmune disease (except stable type 1 diabetes, vitiligo, thyroid disease, or autoimmune alopecia without immunosuppressive treatment)
- Use of systemic steroids or immunosuppressive therapy within 14 days before vaccine start (inhaled/topical steroids allowed without active autoimmune disease)
- Acute infection requiring therapy (therapy must be completed at least 7 days prior to vaccine)
- Received live or attenuated vaccines within 28 days prior to vaccine start (inactive vaccines allowed)
- Received other investigational agents within 4 weeks prior to vaccine start
- Received systemic therapy within 3 weeks prior to vaccine start
- Prior malignancy treated curatively and without recurrence for less than 5 years (except certain skin cancers)
- Any condition or circumstance that may interfere with study participation or results
- Unable to comply with study procedures or follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
Research Team
B
Beth Crump, RN, BSN
CONTACT
T
Thomas Bogenrieder, MD, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here